1. Home
  2. GCT vs ORKA Comparison

GCT vs ORKA Comparison

Compare GCT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCT

GigaCloud Technology Inc

HOLD

Current Price

$40.10

Market Cap

1.5B

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$31.23

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCT
ORKA
Founded
2019
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
GCT
ORKA
Price
$40.10
$31.23
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$24.00
$48.20
AVG Volume (30 Days)
507.9K
643.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
4.32
N/A
EPS
3.31
N/A
Revenue
$1,222,932,000.00
N/A
Revenue This Year
$9.56
N/A
Revenue Next Year
$7.08
N/A
P/E Ratio
$12.26
N/A
Revenue Growth
10.17
N/A
52 Week Low
$11.17
$5.49
52 Week High
$43.85
$32.64

Technical Indicators

Market Signals
Indicator
GCT
ORKA
Relative Strength Index (RSI) 61.93 53.61
Support Level $38.89 $27.84
Resistance Level $41.50 $32.64
Average True Range (ATR) 1.96 1.92
MACD -0.27 0.00
Stochastic Oscillator 40.25 56.46

Price Performance

Historical Comparison
GCT
ORKA

About GCT GigaCloud Technology Inc

GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: